AI assistant
IMUGENE LIMITED — Capital/Financing Update 2015
Oct 27, 2015
65124_rns_2015-10-27_aced485e-af5a-41ad-b740-e9e4272e4e26.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Suite 1, 1233 High Street Armadale VIC 3142
==> picture [175 x 57] intentionally omitted <==
Imugene Limited ACN 009 179 551
28 October 2015
Imugene Receives $755K Research and Development Tax Refund
Imugene Limited (ASX:IMU) has received a research and development tax refund of $755,854 as part of the Australian government’s R&D incentive program.
These funds complement Imugene’s $3 million capital raising announced in September and will contribute to the progression of the company’s main asset, HER-Vaxx, due to enter additional human Phase Ib/II gastric cancer clinical trials in 2016.
“This is valuable non-dilutive capital for Imugene. If we succeed in commercialising HER-Vaxx, it will mean a potential Australian blockbuster drug and a better treatment for people who suffer HER2-positive gastric, breast and other cancers,” said Ms Leslie Chong, Chief Operating Officer of Imugene.
“Australia is a great source of medical innovations and this funding helps our company and others to convert those innovations to commercial tangible outcomes.”
Leslie Chong Chief Operating Officer Paul Hopper Tel: +61 458 040 433 Executive Chairman [email protected] Tel: +61 406 671 515 www.imugene.com [email protected]
Media contact: Rudi Michelson Monsoon Communications +61 3 9620 3333 rudim[@monsoon.com.au
About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.
IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com